Novartis Pharmaceuticals Corp. agreed earlier this month to pay $678 million to settle an SDNY False Claims Act case. The SDNY alleged that Novartis violated the False Claims Act and the Anti-Kickback Statute by giving doctors cash payments, exorbitant speaker fees, and expensive dinners to induce them to prescribe Novartis cardiovascular and diabetes drugs. The
More Posts
Compound Pharmacies Enter False Claims Act And Anti-Kickback Statute Settlement
EDNY Courts Enjoin Transmission of Fraudulent Robocalls
Second Circuit Holds Case Challenging Marijuana Classification As Schedule I Drug In Abeyance Pending Agency Exhaustion
Second Circuit Holds Case Challenging Marijuana Classification As Schedule I Drug In Abeyance Pending Agency Exhaustion
Supreme Court Unanimously Decides Relator May Use Ten-Year Limitation Period In Declined FCA Case
DOJ Outlines Guidance For Cooperation Credit in False Claims Act Cases
MTA Required To Provide Disability Access In Subway Station Renovation Unless Technically Infeasible
Home Health Care Aides Working Twenty-Four Hour Shifts Can Be Paid For Thirteen Hours If Employer Meets Sleep and Meal Time Requirements
Fugitive Relator’s Alternate Remedy Claim For Part Of $25.6 Million FCA Settlement Fails In Second Circuit
Subscribe: Subscribe via RSS